In the 2020 election, Oregon voters demonstrated an overwhelming appetite for drug policy reform. Election results show landslide victories for two groundbreaking measures – one decriminalizing all drugs, and one legalizing psilocybin-assisted clinical sessions. Both measures came to the ballot as … Read more about Oregon Takes the Lead on Drug Policy Reform
Revisiting the War on Drugs & Its Impact
July 14 marked the 50th anniversary of President Richard Nixon’s message to Congress asking for the establishment of a federal plan to tackle substance abuse, citing a dramatic increase in juvenile arrests for drug offenses. Nixon’s letter was the start of a new era of American drug policy as, the … Read more about Revisiting the War on Drugs & Its Impact
Psychedelic Medicine’s Rise in 2019
Late March of 2019, a collection of European technology investors made waves in the psychedelic medicine industry, amassing the largest-ever private financing round for biotech company, ATAI Life Sciences (“ATAI”). According to ATAI’s press release, the German-based company’s Series B financing … Read more about Psychedelic Medicine’s Rise in 2019
MAPS Announces Progress in Two PTSD Studies
In the organization’s monthly newsletter, the Multidisciplinary Association for Psychedelic Studies (“MAPS”) announced two milestones in separately conducted clinical trials, both dedicated to the treatment of post-traumatic stress disorder (“PTSD”). This month, MAPS received approval for the … Read more about MAPS Announces Progress in Two PTSD Studies
Iowa Bill to Legalize Psilocybin Mushrooms and MDMA
In a surprising move late last week, Iowa Rep. Jeff Shipley (R) filed two pieces of legislation in the Iowa state legislature to legalize specific psychedelic substances as treatments. The first bill would approve the medical use of psilocybin, methylenedioxymethamphetamine (“MDMA”), and ibogaine – … Read more about Iowa Bill to Legalize Psilocybin Mushrooms and MDMA
MDMA-Assisted Psychotherapy Study Expands Screening
Multidisciplinary Association for Psychedelic Studies (“MAPS”), a non-profit research, advocacy, and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and empathogens, has recently announced the expansion of their … Read more about MDMA-Assisted Psychotherapy Study Expands Screening